Clinical trial
Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)
NCT00237393 · Ralph H. Johnson VA Medical Center, U.S. Fed · Completed
Key facts
| NCT number | NCT00237393 |
|---|---|
| Title | Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD) |
| Official title | A Randomized, Placebo-Controlled Trial of Quetiapine (Seroquel) Monotherapy in the Treatment of PTSD |
| Acronym | PTSD |
| Lead sponsor | Ralph H. Johnson VA Medical Center, U.S. Fed |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | PTSD |
| Intervention type | Drug |
| Interventions | Quetiapine, Placebo |
| Enrollment | 80 |
| Start date | Aug 1, 2003 |
| Completion | Dec 1, 2007 |
| First posted | Oct 12, 2005 |
| Last update posted | Feb 21, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: